SCHEMBL11297575

SCHEMBL11297575

Nc1ccc(C2CCNCC2)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QDPR P09417 1/20 0.51
CYP2D6 P10635 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KCNH2 Q12809 1/20 0.46
HTR2C P28335 8/20 0.46
SLC18A3 Q16572 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
HTR3A P46098 2/20 0.44
CYP3A4 P08684 2/20 0.41
TSHR P16473 2/20 0.41
TLR9 Q9NR96 1/20 0.40
TLR8 Q9NR97 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
P2RX7 Q99572 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
USP7 Q93009 1/20 0.39
HTR1A P08908 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14167565 0.90 CYP2D6 (0.59) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL854929 0.87 CYP3A4 (0.48) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
Tert-Butyl Formate SCHEMBL27945506 0.84 QDPR (0.38) QDPRCYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL3781164 0.83 SLC6A2 (0.50) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL3789570 0.83 SLC6A2 (0.46) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL2711302 0.83 SLC6A2 (0.64) QDPRCYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL3786337 0.81 SLC6A2 (0.49) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
Hydrochloric Acid SCHEMBL2160176 0.81 SLC6A2 (0.62) QDPRCYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL14167556 0.81 CYP2D6 (0.67) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL5585044 0.79 SLC6A2 (0.58) QDPRCYP2D6SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9212192-B2 Bicyclic carboxamide inhibitors of kinases ABBVIE INC. (US) 2015-12-15 US disclosed
US-20140194418-A1 BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES ABBVIE INC. (US) 2014-07-10 US disclosed
EP-2665727-A1 BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 EP disclosed
WO-2012097684-A1 BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194418-A1 BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES ALK, BRAF, BMX QDPR 1630/4885CYP2D6 2416/4885SLC6A2 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.